HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitis.

AbstractPURPOSE:
To describe a case of orbital cellulitis arising in a patient treated with an anti-TNFalpha agent.
DESIGN:
Single interventional case report.
METHODS:
A 42-year-old man developed severe unilateral orbital cellulitis while receiving infliximab (Remicade, Centocor) treatment for Ankylosing spondylitis (AS) as part of the open-label phase of a trial conducted at our tertiary referral center. Cultures grew Staphylococcus aureus.
RESULTS:
Infliximab treatment was stopped and the patient made a full recovery after receiving appropriate antibiotic therapy. Infliximab therapy was resumed after three weeks.
CONCLUSIONS:
Clinical vigilance is warranted when treating patients with anti-TNFalpha agents as these are associated with a diverse and growing number of ophthalmic complications. Resolved infection does not preclude the use of such agents.
AuthorsJonathan C P Roos, Andrew J K Ostor
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 141 Issue 4 Pg. 767-9 (Apr 2006) ISSN: 0002-9394 [Print] United States
PMID16564827 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Amoxicillin-Potassium Clavulanate Combination
  • Infliximab
  • Cefotaxime
Topics
  • Adult
  • Amoxicillin-Potassium Clavulanate Combination (therapeutic use)
  • Anti-Bacterial Agents (therapeutic use)
  • Antibodies, Monoclonal (adverse effects)
  • Cefotaxime (therapeutic use)
  • Cellulitis (diagnosis, drug therapy, etiology)
  • Drug Therapy, Combination
  • Eye Infections, Bacterial (diagnosis, drug therapy, etiology)
  • Humans
  • Infliximab
  • Male
  • Microbial Sensitivity Tests
  • Orbital Diseases (diagnosis, drug therapy, etiology)
  • Randomized Controlled Trials as Topic
  • Spondylitis, Ankylosing (drug therapy)
  • Staphylococcal Infections (diagnosis, drug therapy, etiology)
  • Staphylococcus aureus (isolation & purification)
  • Tumor Necrosis Factor-alpha (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: